SCHEMBL10074711

SCHEMBL10074711

CC(C(=O)NCC(C)(C)CNC(=O)C(O)C(N)COCc1ccccc1)C(N)Cc1cc(F)ccc1F

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
REN P00797 5/20 0.39
LAP3 P28838 2/20 0.38
ANPEP P15144 1/20 0.38
RNPEP Q9H4A4 1/20 0.38
DNPEP Q9ULA0 1/20 0.38
DPP4 P27487 4/20 0.37
DPP7 Q9UHL4 4/20 0.37
DPP9 Q86TI2 2/20 0.37
CTSS P25774 2/20 0.36
CTSB P07858 1/20 0.36
PSMB5 P28074 1/20 0.35
BACE1 P56817 1/20 0.35
MC4R P32245 1/20 0.35
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
ADRB3 P13945 1/20 0.35
CARM1 Q86X55 1/20 0.34
PRMT6 Q96LA8 1/20 0.34
DPP8 Q6V1X1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6874198 0.90 LAP3 (0.48) RENLAP3ANPEPRNPEPDNPEP
SCHEMBL10078267 0.90 REN (0.37) RENLAP3ANPEPRNPEPDNPEP
SCHEMBL10074716 0.90 REN (0.37) RENLAP3ANPEPRNPEPDNPEP
SCHEMBL10074129 0.90 REN (0.37) RENLAP3ANPEPRNPEPDNPEP
SCHEMBL10074326 0.88 DPP4 (0.41) RENDPP4DPP7DPP9DPP8
SCHEMBL10074457 0.88 DPP4 (0.41) RENDPP4DPP7DPP9DPP8
SCHEMBL10074281 0.86 DPP4 (0.41) RENDPP4DPP7DPP9DPP8
SCHEMBL10078259 0.83 SYK (0.37) RENCTSSCTSBMC4RADRB2
SCHEMBL10074471 0.83 SYK (0.37) RENCTSSCTSBMC4RADRB2
SCHEMBL10074722 0.83 SYK (0.37) RENCTSSCTSBMC4RADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2418196-A1 Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors IMTM GmbH (DE) 2012-02-15 EP disclosed
US-20120028995-A1 NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS IMTM GMBH (DE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028995-A1 NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS SERPINB1, CMA1, CPA3 REN 449/4885LAP3 186/4885ANPEP 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.